Belantamab mafodotin is a B-cell maturation antigen (BCMA)-targeted ADC that received accelerated approval in 2020 for relapsed or refractory multiple myeloma after at least four prior therapies (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.